DescriptionCurator's Comment: description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5176be07-3121-49fb-9eb9-638903753a31 | https://www.drugs.com/monograph/atracurium-besylate.html | http://www.wikidoc.org/index.php/Atracurium
Curator's Comment: description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5176be07-3121-49fb-9eb9-638903753a31 | https://www.drugs.com/monograph/atracurium-besylate.html | http://www.wikidoc.org/index.php/Atracurium
Atracurium is an intermediate-duration, nondepolarizing, skeletal muscle relaxant for intravenous administration. It is used, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Most adverse reactions were suggestive of histamine release. Common side effects include flushing of the skin and low blood pressure. Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2362997 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19417616 |
169.5 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | ATRACURIUM BESYLATE Approved UseAtracurium Besylate Injection, USP is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Launch Date1997 |
PubMed
Title | Date | PubMed |
---|---|---|
Synthesis and structure-activity relationships of neuromuscular blocking agents. | 2002 Aug |
|
[Relaxation and the electromyographic identification of the recurrent laryngeal nerve]. | 2002 Sep |
|
[Interaction of donepezil and muscular blockers in Alzheimer's disease]. | 2003 Feb |
|
A comparison of the efficacy of cisatracurium and atracurium in kidney transplantation operation. | 2004 Jan |
|
[Establishment of a hypothermic dog model to investigate airway rewarming]. | 2006 Aug |
|
Dynamic encoding of natural luminance sequences by LGN bursts. | 2006 Jul |
|
Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. | 2007 Jun |
|
Timing precision in population coding of natural scenes in the early visual system. | 2008 Dec 16 |
|
Anaesthetic management of post-burn contractures, a recurrent challenge from oil pipeline vandalization in Nigeria: a case report. | 2009 Dec 3 |
|
Leaking abdominal aortic aneurysm on anticoagulants-thromboelastography assisted management. | 2009 Jun |
|
A prospective randomized double blind study to evaluate the effect of infusion of amino Acid enriched solution on recovery from neuromuscular blockade. | 2009 Jun |
|
Modulation of temporal precision in thalamic population responses to natural visual stimuli. | 2010 |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
Comparison between Culture Conditions Improving Growth and Differentiation of Blood and Bone Marrow Cells Committed to the Endothelial Cell Lineage. | 2010 Feb 6 |
|
Marfan syndrome with acute abdomen: a case report. | 2010 Nov 10 |
|
Cisatracurium in different doses versus atracurium during general anesthesia for abdominal surgery. | 2010 Sep |
|
Wound contraction and macro-deformation during negative pressure therapy of sternotomy wounds. | 2010 Sep 30 |
Patents
Sample Use Guides
An atracurium besylate dose of 0.4 to 0.5 mg/kg (1.7 to 2.2 times the ED95), given as an intravenous bolus injection, is the recommended initial dose for most patients. Maximum neuromuscular block achieved approximately 3 to 5 minutes after injection.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2720863
Exposure of isolated rat hepatocytes to atracurium produced cellular damage evidenced by extrusion of an intracellular enzyme, lactate dehydrogenase (LDH), into the incubation medium. Leakage of LDH was directly related to the concentration of atracurium in the medium (250 to 800 microM). When atracurium was added to the medium and the medium immediately added to hepatocytes, the leakage of LDH increased as the concentration of atracurium increased (P < 0.001 for the comparison with cells not exposed to atracurium).
Substance Class |
Mixture
Created
by
admin
on
Edited
Fri Dec 15 16:08:13 GMT 2023
by
admin
on
Fri Dec 15 16:08:13 GMT 2023
|
Record UNII |
40AX66P76P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29696
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4734
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
SUB05603MIG
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
264-743-4
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
DB00732
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
1219
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | RxNorm | ||
|
C28839
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
CHEMBL1360
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
760047
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
DTXSID6022630
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
64228-81-5
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
m2129
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | Merck Index | ||
|
40AX66P76P
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
ATRACURIUM BESILATE
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
1044800
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
2915
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
T-90
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY | |||
|
40AX66P76P
Created by
admin on Fri Dec 15 16:08:13 GMT 2023 , Edited by admin on Fri Dec 15 16:08:13 GMT 2023
|
PRIMARY |
All of the following components must be present:
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |